Wednesday, February 12, 2020, San Francisco, California, 7:15 PM – 9:00 PM

Consensus or Controversy? Clinical Investigators Discuss the Optimal Management of Metastatic Renal Cell Carcinoma

Location
W San Francisco
181 Third Street
San Francisco, CA 94103
Hotel Phone: (415) 777-5300

Time
7:00 PM – 7:15 PM — Registration
7:15 PM – 9:00 PM — Educational Dinner Meeting

Meeting Room
Social Terrace (Fourth Floor)

There is no registration fee for this event. However, preregistration is advised as seating is limited.  
 
Faculty
Toni K Choueiri, MD
Director, Lank Center for Genitourinary Oncology
Department of Medical Oncology
Dana-Farber Cancer Institute
Co-Leader, Kidney Cancer Program
Dana-Farber/Harvard Cancer Center
The Jerome and Nancy Kohlberg Professor
of Medicine
Harvard Medical School
Boston, Massachusetts

Thomas E Hutson, DO, PharmD
Director, GU Oncology Program
Co-Director, Urologic Cancer Research and Treatment Center
Texas Oncology
Charles A Sammons Cancer Center
Baylor University Medical Center
Professor of Medicine
Texas A&M HSC College of Medicine
Dallas, Texas

David F McDermott, MD
Chief, Medical Oncology
Beth Israel Deaconess Medical Center
Leader, Kidney Cancer Program
Dana-Farber/Harvard Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Thomas Powles, MBBS, MRCP, MD
Professor of Genitourinary Oncology
Barts Cancer Institute
Director of Barts Cancer Centre
Queen Mary University of London
London, United Kingdom

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


Not an official event of the 2020 Genitourinary Cancers Symposium. Not sponsored, endorsed, or accredited by any of the cosponsoring organizations of the 2020 Genitourinary Cancers Symposium.

Event Schedule

7:00 PM – 7:15 PM — Registration
7:15 PM – 9:00 PM — Educational Dinner Meeting

MODULE 1: Optimizing Front-Line Decision-Making for Advanced Renal Cell Carcinoma (RCC)

  • Major efficacy and safety findings from the pivotal Phase III CheckMate 214 trial evaluating nivolumab/ipilimumab versus sunitinib for treatment-naïve advanced RCC
  • Design, eligibility criteria and key efficacy and safety data from the Phase III KEYNOTE-426 and JAVELIN Renal 101 trials assessing pembrolizumab/axitinib and avelumab/axitinib, respectively, in the front-line setting; similarities and differences between trial designs and available results
  • FDA approvals of pembrolizumab/axitinib and avelumab/axitinib and optimal integration into clinical practice
  • Published research data with and FDA approval of cabozantinib as first-line therapy; current role of tyrosine kinase inhibitor (TKI) monotherapy for patients with newly diagnosed metastatic RCC
  • Clinical and biologic factors influencing the selection of first-line therapy for patients with newly diagnosed metastatic RCC
  • Available data with various agents and combination regimens in patients with brain metastases

MODULE 2: Selection and Sequencing of Therapy for Patients with Relapsed/Refractory (R/R) RCC

  • Rational sequencing of available therapies for metastatic RCC progressing on front-line treatment; patient-specific factors affecting decision-making in this setting (eg, prior systemic therapy, performance status, comorbidities)
  • Available clinical trial findings with and clinical use of cabozantinib for patients with R/R RCC
  • Design, eligibility criteria and primary and secondary endpoints of the Phase II BREAKPOINT trial evaluating the role of cabozantinib for patients who have previously received checkpoint inhibitor therapy
  • Available data with and patient selection for anti-PD-1 monotherapy for R/R disease
  • Published research data with and optimal integration of lenvatinib/everolimus into current RCC management algorithms

MODULE 3: Novel Strategies Under Investigation in RCC

  • Findings from the Phase III IMmotion151 study of atezolizumab/bevacizumab versus sunitinib for patients with untreated PD-L1-positive metastatic RCC; potential clinical role of atezolizumab/bevacizumab
  • Published research findings leading to the FDA breakthrough therapy designation for front-line pembrolizumab/lenvatinib
  • Design, eligibility criteria and primary and secondary endpoints of the Phase III CLEAR trial evaluating lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone as first-line therapy for advanced RCC
  • Other ongoing Phase III studies (ie, PDIGREE, CheckMate 9ER, COSMIC-313) investigating anti-PD-1/PD-L1 antibody/TKI combinations in previously untreated advanced RCC
  • Available clinical trial data with and ongoing evaluation of other novel agents (eg, bempegaldesleukin, PT2977, pegilodecakin)
  • Biologic rationale for and ongoing clinical trials of immune checkpoint inhibitors as adjuvant or neoadjuvant therapy for intermediate- to high-risk localized RCC

MODULE 4: Identification and Management of Adverse Events Associated with Immune Checkpoint Inhibitor and TKI Therapy

  • Incidence, severity and timing of immune-related adverse events in Phase III first-line combination trials (eg, CheckMate 214, KEYNOTE-426, JAVELIN Renal 101); rates and causes of treatment discontinuation
  • Comparative tolerability of various front-line approaches (eg, ipilimumab/nivolumab versus pembrolizumab/axitinib or avelumab/axitinib versus cabozantinib)
  • Pathophysiology of common and uncommon adverse events observed with the use of anti-PD-1/PD-L1 antibodies alone or in combination with other immune checkpoint inhibitors or TKIs
  • Recommended algorithms for the management of immune-related adverse events; indications for restarting immune checkpoint inhibitor therapy after resolution of symptoms

Target Audience
This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals involved in the treatment of renal cell carcinoma (RCC).

Learning Objectives
At the conclusion of this activity, participants should be able to:

  • Effectively apply evidence-based research findings and other clinical and biologic factors in the best-practice selection of first-line therapy for patients with metastatic RCC (mRCC).
  • Develop an evidence-based approach to the sequencing of systemic therapies for patients with advanced RCC, incorporating tyrosine kinase inhibitors, anti-VEGF antibodies, mTOR inhibitors and immunotherapeutic approaches.
  • Recall the underlying research database supporting the FDA approval of anti-PD-1/anti-CTLA-4 combination therapy as first-line treatment for patients with mRCC, and develop strategies to appropriately integrate this strategy into the care of these individuals.
  • Appraise available clinical trial data evaluating the use of recently FDA-approved anti-PD-1/PD-L1 antibody/multikinase inhibitor combinations for patients with previously untreated mRCC, and counsel individuals with the disease regarding the risks and benefits of these novel regimens.
  • Develop a rational therapeutic approach to the sequencing of systemic therapies for patients with advanced RCC who progress on first-line treatment, incorporating tyrosine kinase inhibitors, anti-VEGF antibodies, mTOR inhibitors and immunotherapeutic agents.
  • Recognize side effects and toxicities commonly associated with approved and investigational therapeutic approaches, and use this information to develop supportive management plans for patients with RCC undergoing treatment with these agents and regimens.
  • Recall available and emerging data with other investigational agents and strategies currently in testing for RCC and, where applicable, refer eligible patients for clinical trial participation.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Supporters
This activity is supported by educational grants from Eisai Inc, Exelixis Inc and Merck.

W San Francisco
181 Third Street
San Francisco, CA 94103
Hotel Phone: (415) 777-5300

Meeting Room
Social Terrace (Fourth Floor)

Directions
The W San Francisco is located just 1 block (less than 0.1 miles) from the Moscone Convention Center, where the 2020 Genitourinary Cancers Symposium is taking place.

This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals involved in the treatment of renal cell carcinoma.

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
 
Registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future CME programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.